Clinical outcomes of allogeneic stem cell transplantation for relapsed or refractory follicular lymphoma: a retrospective analysis by the Fukuoka Blood and Marrow Transplantation Group
Allogeneic hematopoietic stem cell transplantation (allo-SCT) is considered the only curative treatment for relapsed or refractory follicular lymphoma (FL), but it has a high treatment-related mortality rate. Only a few reports, however, have described the efficacy of allo-SCT for FL in the Japanese...
Gespeichert in:
| Veröffentlicht in: | International journal of hematology 2013-10, Vol.98 (4), p.463-471 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 471 |
|---|---|
| container_issue | 4 |
| container_start_page | 463 |
| container_title | International journal of hematology |
| container_volume | 98 |
| creator | Ito, Yoshikiyo Miyamoto, Toshihiro Kamimura, Tomohiko Takase, Ken Henzan, Hideho Sugio, Yasuo Kato, Koji Ohno, Yuju Eto, Tetsuya Teshima, Takanori Akashi, Koichi |
| description | Allogeneic hematopoietic stem cell transplantation (allo-SCT) is considered the only curative treatment for relapsed or refractory follicular lymphoma (FL), but it has a high treatment-related mortality rate. Only a few reports, however, have described the efficacy of allo-SCT for FL in the Japanese population. We retrospectively analyzed the outcome of allo-SCT in 30 patients with FL. Seventeen (56.7 %) patients were chemorefractory, whereas 13 (43.3 %) were chemosensitive. An estimated 2-year overall survival rate (OS) and relapse rate of all patients was 46.7 and 20.0 %, respectively. There were no significant differences in the estimated 2-year OS rate between patients who received myeloablative conditioning and those who received reduced-intensity conditioning (
P
= 0.98), and among the recipients of related bone marrow (BM)/peripheral blood stem cell, unrelated BM and umbilical cord blood (
P
= 0.20). In patients who were either chemosensitive or chemorefractory at allo-SCT, the 2-year OS rate was 69.2 and 29.4 % (
P
= 0.06). Patients with mild-to-moderate acute GVHD had better 2-year PFS rate compared with patients who had severe acute GVHD (
P
= 0.01), but not better PFS compared with patients who had no acute GVHD (
P
= 0.12). Our results suggest that the graft-versus-lymphoma effects of allo-SCT may provide survival benefits even in patients with chemorefractory FL. |
| doi_str_mv | 10.1007/s12185-013-1430-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1444392651</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1444392651</sourcerecordid><originalsourceid>FETCH-LOGICAL-c589t-50208faf26f36e5d3190917341aebb3f18dde775ad7c269f9cf499dbbaa19a7f3</originalsourceid><addsrcrecordid>eNp1kc9uFSEUh4nR2Gv1AdwYEmPiZhQGGAZ39cZWkxo3dT05w0BLywwjMJp5sz5eub3XP2niCpLznXPg9yH0kpJ3lBD5PtGatqIilFWUM1KpR2hD20ZUTEr-GG2IqkUlJCVH6FlK14RQSbh8io5qTjgTbb1Bt1vvJqfB47BkHUaTcLAYvA-XZjJO45TNiLXxHucIU5o9TBmyCxO2IeJoPMzJDPj-biPoHOJaSt47vXiI2K_jfBVG-IChEDmGNBud3U-DYQK_Jpdwv-J8ZfDpcrOEG8AffQhDqQ74K8QYfuGLB4vPYljm5-iJBZ_Mi8N5jL6ffrrYfq7Ov5192Z6cV1q0KleC1KS1YOvGssaIgVFFFJWMUzB9zyxth8FIKWCQum6UVdpypYa-B6AKpGXH6O1-7hzDj8Wk3I0u7fKAyYQldZRzzlTdCFrQ1w_Q67DE8st7ijVUUiUKRfeULlmkElo3RzdCXDtKup3Wbq-1K1q7ndZOlZ5Xh8lLP5rhT8dvjwV4cwAgFZlFxKRd-stJRUgr28LVey6V0nRp4j9P_O_2O0aGvxU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1443617195</pqid></control><display><type>article</type><title>Clinical outcomes of allogeneic stem cell transplantation for relapsed or refractory follicular lymphoma: a retrospective analysis by the Fukuoka Blood and Marrow Transplantation Group</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Ito, Yoshikiyo ; Miyamoto, Toshihiro ; Kamimura, Tomohiko ; Takase, Ken ; Henzan, Hideho ; Sugio, Yasuo ; Kato, Koji ; Ohno, Yuju ; Eto, Tetsuya ; Teshima, Takanori ; Akashi, Koichi</creator><creatorcontrib>Ito, Yoshikiyo ; Miyamoto, Toshihiro ; Kamimura, Tomohiko ; Takase, Ken ; Henzan, Hideho ; Sugio, Yasuo ; Kato, Koji ; Ohno, Yuju ; Eto, Tetsuya ; Teshima, Takanori ; Akashi, Koichi</creatorcontrib><description>Allogeneic hematopoietic stem cell transplantation (allo-SCT) is considered the only curative treatment for relapsed or refractory follicular lymphoma (FL), but it has a high treatment-related mortality rate. Only a few reports, however, have described the efficacy of allo-SCT for FL in the Japanese population. We retrospectively analyzed the outcome of allo-SCT in 30 patients with FL. Seventeen (56.7 %) patients were chemorefractory, whereas 13 (43.3 %) were chemosensitive. An estimated 2-year overall survival rate (OS) and relapse rate of all patients was 46.7 and 20.0 %, respectively. There were no significant differences in the estimated 2-year OS rate between patients who received myeloablative conditioning and those who received reduced-intensity conditioning (
P
= 0.98), and among the recipients of related bone marrow (BM)/peripheral blood stem cell, unrelated BM and umbilical cord blood (
P
= 0.20). In patients who were either chemosensitive or chemorefractory at allo-SCT, the 2-year OS rate was 69.2 and 29.4 % (
P
= 0.06). Patients with mild-to-moderate acute GVHD had better 2-year PFS rate compared with patients who had severe acute GVHD (
P
= 0.01), but not better PFS compared with patients who had no acute GVHD (
P
= 0.12). Our results suggest that the graft-versus-lymphoma effects of allo-SCT may provide survival benefits even in patients with chemorefractory FL.</description><identifier>ISSN: 0925-5710</identifier><identifier>EISSN: 1865-3774</identifier><identifier>DOI: 10.1007/s12185-013-1430-9</identifier><identifier>PMID: 24043582</identifier><language>eng</language><publisher>Tokyo: Springer Japan</publisher><subject>Adult ; Aged ; Biological and medical sciences ; Cause of Death ; Clinical outcomes ; Female ; Follow-Up Studies ; Graft Survival ; Graft vs Host Disease - etiology ; Graft vs Host Disease - prevention & control ; Hematologic and hematopoietic diseases ; Hematology ; Hematopoietic Stem Cell Transplantation - adverse effects ; Humans ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Lymphoma, Follicular - mortality ; Lymphoma, Follicular - pathology ; Lymphoma, Follicular - therapy ; Male ; Medical sciences ; Medicine ; Medicine & Public Health ; Middle Aged ; Neoplasm Recurrence, Local ; Oncology ; Original Article ; Retrospective Studies ; Transplantation Conditioning ; Transplantation, Homologous ; Treatment Outcome</subject><ispartof>International journal of hematology, 2013-10, Vol.98 (4), p.463-471</ispartof><rights>The Japanese Society of Hematology 2013</rights><rights>2014 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c589t-50208faf26f36e5d3190917341aebb3f18dde775ad7c269f9cf499dbbaa19a7f3</citedby><cites>FETCH-LOGICAL-c589t-50208faf26f36e5d3190917341aebb3f18dde775ad7c269f9cf499dbbaa19a7f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12185-013-1430-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12185-013-1430-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27900878$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24043582$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ito, Yoshikiyo</creatorcontrib><creatorcontrib>Miyamoto, Toshihiro</creatorcontrib><creatorcontrib>Kamimura, Tomohiko</creatorcontrib><creatorcontrib>Takase, Ken</creatorcontrib><creatorcontrib>Henzan, Hideho</creatorcontrib><creatorcontrib>Sugio, Yasuo</creatorcontrib><creatorcontrib>Kato, Koji</creatorcontrib><creatorcontrib>Ohno, Yuju</creatorcontrib><creatorcontrib>Eto, Tetsuya</creatorcontrib><creatorcontrib>Teshima, Takanori</creatorcontrib><creatorcontrib>Akashi, Koichi</creatorcontrib><title>Clinical outcomes of allogeneic stem cell transplantation for relapsed or refractory follicular lymphoma: a retrospective analysis by the Fukuoka Blood and Marrow Transplantation Group</title><title>International journal of hematology</title><addtitle>Int J Hematol</addtitle><addtitle>Int J Hematol</addtitle><description>Allogeneic hematopoietic stem cell transplantation (allo-SCT) is considered the only curative treatment for relapsed or refractory follicular lymphoma (FL), but it has a high treatment-related mortality rate. Only a few reports, however, have described the efficacy of allo-SCT for FL in the Japanese population. We retrospectively analyzed the outcome of allo-SCT in 30 patients with FL. Seventeen (56.7 %) patients were chemorefractory, whereas 13 (43.3 %) were chemosensitive. An estimated 2-year overall survival rate (OS) and relapse rate of all patients was 46.7 and 20.0 %, respectively. There were no significant differences in the estimated 2-year OS rate between patients who received myeloablative conditioning and those who received reduced-intensity conditioning (
P
= 0.98), and among the recipients of related bone marrow (BM)/peripheral blood stem cell, unrelated BM and umbilical cord blood (
P
= 0.20). In patients who were either chemosensitive or chemorefractory at allo-SCT, the 2-year OS rate was 69.2 and 29.4 % (
P
= 0.06). Patients with mild-to-moderate acute GVHD had better 2-year PFS rate compared with patients who had severe acute GVHD (
P
= 0.01), but not better PFS compared with patients who had no acute GVHD (
P
= 0.12). Our results suggest that the graft-versus-lymphoma effects of allo-SCT may provide survival benefits even in patients with chemorefractory FL.</description><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Cause of Death</subject><subject>Clinical outcomes</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Graft Survival</subject><subject>Graft vs Host Disease - etiology</subject><subject>Graft vs Host Disease - prevention & control</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hematology</subject><subject>Hematopoietic Stem Cell Transplantation - adverse effects</subject><subject>Humans</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Lymphoma, Follicular - mortality</subject><subject>Lymphoma, Follicular - pathology</subject><subject>Lymphoma, Follicular - therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Retrospective Studies</subject><subject>Transplantation Conditioning</subject><subject>Transplantation, Homologous</subject><subject>Treatment Outcome</subject><issn>0925-5710</issn><issn>1865-3774</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kc9uFSEUh4nR2Gv1AdwYEmPiZhQGGAZ39cZWkxo3dT05w0BLywwjMJp5sz5eub3XP2niCpLznXPg9yH0kpJ3lBD5PtGatqIilFWUM1KpR2hD20ZUTEr-GG2IqkUlJCVH6FlK14RQSbh8io5qTjgTbb1Bt1vvJqfB47BkHUaTcLAYvA-XZjJO45TNiLXxHucIU5o9TBmyCxO2IeJoPMzJDPj-biPoHOJaSt47vXiI2K_jfBVG-IChEDmGNBud3U-DYQK_Jpdwv-J8ZfDpcrOEG8AffQhDqQ74K8QYfuGLB4vPYljm5-iJBZ_Mi8N5jL6ffrrYfq7Ov5192Z6cV1q0KleC1KS1YOvGssaIgVFFFJWMUzB9zyxth8FIKWCQum6UVdpypYa-B6AKpGXH6O1-7hzDj8Wk3I0u7fKAyYQldZRzzlTdCFrQ1w_Q67DE8st7ijVUUiUKRfeULlmkElo3RzdCXDtKup3Wbq-1K1q7ndZOlZ5Xh8lLP5rhT8dvjwV4cwAgFZlFxKRd-stJRUgr28LVey6V0nRp4j9P_O_2O0aGvxU</recordid><startdate>20131001</startdate><enddate>20131001</enddate><creator>Ito, Yoshikiyo</creator><creator>Miyamoto, Toshihiro</creator><creator>Kamimura, Tomohiko</creator><creator>Takase, Ken</creator><creator>Henzan, Hideho</creator><creator>Sugio, Yasuo</creator><creator>Kato, Koji</creator><creator>Ohno, Yuju</creator><creator>Eto, Tetsuya</creator><creator>Teshima, Takanori</creator><creator>Akashi, Koichi</creator><general>Springer Japan</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20131001</creationdate><title>Clinical outcomes of allogeneic stem cell transplantation for relapsed or refractory follicular lymphoma: a retrospective analysis by the Fukuoka Blood and Marrow Transplantation Group</title><author>Ito, Yoshikiyo ; Miyamoto, Toshihiro ; Kamimura, Tomohiko ; Takase, Ken ; Henzan, Hideho ; Sugio, Yasuo ; Kato, Koji ; Ohno, Yuju ; Eto, Tetsuya ; Teshima, Takanori ; Akashi, Koichi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c589t-50208faf26f36e5d3190917341aebb3f18dde775ad7c269f9cf499dbbaa19a7f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Cause of Death</topic><topic>Clinical outcomes</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Graft Survival</topic><topic>Graft vs Host Disease - etiology</topic><topic>Graft vs Host Disease - prevention & control</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hematology</topic><topic>Hematopoietic Stem Cell Transplantation - adverse effects</topic><topic>Humans</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Lymphoma, Follicular - mortality</topic><topic>Lymphoma, Follicular - pathology</topic><topic>Lymphoma, Follicular - therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Retrospective Studies</topic><topic>Transplantation Conditioning</topic><topic>Transplantation, Homologous</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ito, Yoshikiyo</creatorcontrib><creatorcontrib>Miyamoto, Toshihiro</creatorcontrib><creatorcontrib>Kamimura, Tomohiko</creatorcontrib><creatorcontrib>Takase, Ken</creatorcontrib><creatorcontrib>Henzan, Hideho</creatorcontrib><creatorcontrib>Sugio, Yasuo</creatorcontrib><creatorcontrib>Kato, Koji</creatorcontrib><creatorcontrib>Ohno, Yuju</creatorcontrib><creatorcontrib>Eto, Tetsuya</creatorcontrib><creatorcontrib>Teshima, Takanori</creatorcontrib><creatorcontrib>Akashi, Koichi</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ito, Yoshikiyo</au><au>Miyamoto, Toshihiro</au><au>Kamimura, Tomohiko</au><au>Takase, Ken</au><au>Henzan, Hideho</au><au>Sugio, Yasuo</au><au>Kato, Koji</au><au>Ohno, Yuju</au><au>Eto, Tetsuya</au><au>Teshima, Takanori</au><au>Akashi, Koichi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical outcomes of allogeneic stem cell transplantation for relapsed or refractory follicular lymphoma: a retrospective analysis by the Fukuoka Blood and Marrow Transplantation Group</atitle><jtitle>International journal of hematology</jtitle><stitle>Int J Hematol</stitle><addtitle>Int J Hematol</addtitle><date>2013-10-01</date><risdate>2013</risdate><volume>98</volume><issue>4</issue><spage>463</spage><epage>471</epage><pages>463-471</pages><issn>0925-5710</issn><eissn>1865-3774</eissn><abstract>Allogeneic hematopoietic stem cell transplantation (allo-SCT) is considered the only curative treatment for relapsed or refractory follicular lymphoma (FL), but it has a high treatment-related mortality rate. Only a few reports, however, have described the efficacy of allo-SCT for FL in the Japanese population. We retrospectively analyzed the outcome of allo-SCT in 30 patients with FL. Seventeen (56.7 %) patients were chemorefractory, whereas 13 (43.3 %) were chemosensitive. An estimated 2-year overall survival rate (OS) and relapse rate of all patients was 46.7 and 20.0 %, respectively. There were no significant differences in the estimated 2-year OS rate between patients who received myeloablative conditioning and those who received reduced-intensity conditioning (
P
= 0.98), and among the recipients of related bone marrow (BM)/peripheral blood stem cell, unrelated BM and umbilical cord blood (
P
= 0.20). In patients who were either chemosensitive or chemorefractory at allo-SCT, the 2-year OS rate was 69.2 and 29.4 % (
P
= 0.06). Patients with mild-to-moderate acute GVHD had better 2-year PFS rate compared with patients who had severe acute GVHD (
P
= 0.01), but not better PFS compared with patients who had no acute GVHD (
P
= 0.12). Our results suggest that the graft-versus-lymphoma effects of allo-SCT may provide survival benefits even in patients with chemorefractory FL.</abstract><cop>Tokyo</cop><pub>Springer Japan</pub><pmid>24043582</pmid><doi>10.1007/s12185-013-1430-9</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0925-5710 |
| ispartof | International journal of hematology, 2013-10, Vol.98 (4), p.463-471 |
| issn | 0925-5710 1865-3774 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1444392651 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Adult Aged Biological and medical sciences Cause of Death Clinical outcomes Female Follow-Up Studies Graft Survival Graft vs Host Disease - etiology Graft vs Host Disease - prevention & control Hematologic and hematopoietic diseases Hematology Hematopoietic Stem Cell Transplantation - adverse effects Humans Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Lymphoma, Follicular - mortality Lymphoma, Follicular - pathology Lymphoma, Follicular - therapy Male Medical sciences Medicine Medicine & Public Health Middle Aged Neoplasm Recurrence, Local Oncology Original Article Retrospective Studies Transplantation Conditioning Transplantation, Homologous Treatment Outcome |
| title | Clinical outcomes of allogeneic stem cell transplantation for relapsed or refractory follicular lymphoma: a retrospective analysis by the Fukuoka Blood and Marrow Transplantation Group |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T01%3A59%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20outcomes%20of%20allogeneic%20stem%20cell%20transplantation%20for%20relapsed%20or%20refractory%20follicular%20lymphoma:%20a%20retrospective%20analysis%20by%20the%20Fukuoka%20Blood%20and%20Marrow%20Transplantation%20Group&rft.jtitle=International%20journal%20of%20hematology&rft.au=Ito,%20Yoshikiyo&rft.date=2013-10-01&rft.volume=98&rft.issue=4&rft.spage=463&rft.epage=471&rft.pages=463-471&rft.issn=0925-5710&rft.eissn=1865-3774&rft_id=info:doi/10.1007/s12185-013-1430-9&rft_dat=%3Cproquest_cross%3E1444392651%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1443617195&rft_id=info:pmid/24043582&rfr_iscdi=true |